1. Home
  2. RMCF vs BIVI Comparison

RMCF vs BIVI Comparison

Compare RMCF & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rocky Mountain Chocolate Factory Inc.

RMCF

Rocky Mountain Chocolate Factory Inc.

N/A

Current Price

$0.73

Market Cap

14.9M

ML Signal

N/A

Logo BioVie Inc.

BIVI

BioVie Inc.

N/A

Current Price

$1.15

Market Cap

12.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RMCF
BIVI
Founded
1981
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.9M
12.4M
IPO Year
2024
2013

Fundamental Metrics

Financial Performance
Metric
RMCF
BIVI
Price
$0.73
$1.15
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $5.26
AVG Volume (30 Days)
24.0K
★ 811.3K
Earning Date
10-19-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
34.88
★ 74.83
EPS
★ N/A
N/A
Revenue
★ $30,432,352.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.66
$0.82
52 Week High
$2.99
$3.79

Technical Indicators

Market Signals
Indicator
RMCF
BIVI
Relative Strength Index (RSI) 34.56 41.73
Support Level $0.66 $1.15
Resistance Level $1.19 $1.47
Average True Range (ATR) 0.06 0.22
MACD -0.01 -0.01
Stochastic Oscillator 2.61 3.54

Price Performance

Historical Comparison
RMCF
BIVI

About RMCF Rocky Mountain Chocolate Factory Inc.

Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The company prepares numerous products, including caramel apples in the store. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, and Others. The company derives maximum revenue through manufacturing activities. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.

Share on Social Networks: